These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 28688543)

  • 1. Liver steatosis: The new epidemic of the Third Millennium. Benign liver state or silent killer?
    Puoti C; Elmo MG; Ceccarelli D; Ditrinco M
    Eur J Intern Med; 2017 Dec; 46():1-5. PubMed ID: 28688543
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Non-alcoholic Fatty Liver Disease (NAFLD)--A Review.
    Karim MF; Al-Mahtab M; Rahman S; Debnath CR
    Mymensingh Med J; 2015 Oct; 24(4):873-80. PubMed ID: 26620035
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pediatric non-alcoholic fatty liver disease: Recent solutions, unresolved issues, and future research directions.
    Clemente MG; Mandato C; Poeta M; Vajro P
    World J Gastroenterol; 2016 Sep; 22(36):8078-93. PubMed ID: 27688650
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nonalcoholic Fatty Liver Disease: Pathophysiology and Management.
    Carr RM; Oranu A; Khungar V
    Gastroenterol Clin North Am; 2016 Dec; 45(4):639-652. PubMed ID: 27837778
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic value of high sensitivity C-reaction protein in non-insulin dependent diabetes mellitus patients with non-alcoholic fatty liver disease.
    Bi Y; Min M; Shen W; Deng P; Du Q; Dong M; Liu Y
    Int J Clin Exp Pathol; 2015; 8(7):8494-9. PubMed ID: 26339423
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cardiovascular risk across the histological spectrum and the clinical manifestations of non-alcoholic fatty liver disease: An update.
    Athyros VG; Tziomalos K; Katsiki N; Doumas M; Karagiannis A; Mikhailidis DP
    World J Gastroenterol; 2015 Jun; 21(22):6820-34. PubMed ID: 26078558
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pediatric Non-alcoholic Fatty Liver Disease.
    Uppal V; Mansoor S; Furuya KN
    Curr Gastroenterol Rep; 2016 May; 18(5):24. PubMed ID: 27086005
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Paediatric non-alcoholic fatty liver disease: a practical overview for non-specialists.
    Mann JP; Goonetilleke R; McKiernan P
    Arch Dis Child; 2015 Jul; 100(7):673-7. PubMed ID: 25633064
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nonalcoholic Fatty Liver Disease.
    Sweet PH; Khoo T; Nguyen S
    Prim Care; 2017 Dec; 44(4):599-607. PubMed ID: 29132522
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Managing non-alcoholic fatty liver disease.
    Ngu JH; Goh GB; Poh Z; Soetikno R
    Singapore Med J; 2016 Jul; 57(7):368-71. PubMed ID: 27439352
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Non-alcoholic fatty liver disease in obese adults: clinical aspects and current management strategies.
    Pallayova M; Taheri S
    Clin Obes; 2014 Oct; 4(5):243-53. PubMed ID: 25825857
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hepatic Steatosis as a Marker of Metabolic Dysfunction.
    Fabbrini E; Magkos F
    Nutrients; 2015 Jun; 7(6):4995-5019. PubMed ID: 26102213
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metabolic Syndrome: Nonalcoholic Fatty Liver Disease.
    Williams T
    FP Essent; 2015 Aug; 435():24-9. PubMed ID: 26280342
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The diagnostics and clinical pattern of nonalcoholic fatty liver disease in patients with pre-diabetes and type 2 diabetes and obesity].
    Чубірко КІ
    Wiad Lek; 2017; 70(2):208-212. PubMed ID: 28511161
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nonalcoholic fatty liver disease, metabolic risk factors, and hepatocellular carcinoma: an open question.
    Streba LA; Vere CC; Rogoveanu I; Streba CT
    World J Gastroenterol; 2015 Apr; 21(14):4103-10. PubMed ID: 25892859
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Non-alcoholic fatty liver disease as a cause and a consequence of metabolic syndrome.
    Yki-Järvinen H
    Lancet Diabetes Endocrinol; 2014 Nov; 2(11):901-10. PubMed ID: 24731669
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The diagnosis and treatment of non-alcoholic fatty liver disease.
    Altinbas A; Sowa JP; Hasenberg T; Canbay A
    Minerva Gastroenterol Dietol; 2015 Sep; 61(3):159-69. PubMed ID: 26080905
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination of Aspartate Aminotranferase and Tumor Necrosis Factor-α as Non Invasive Diagnostic Tools for Non Alcoholic Steatohepatitis (NASH).
    Purnomo HD; Mundhofir FE; Kasno ; Sudijanto E; Darmono ; Daldiyono ; Djokomoeljanto R; Faradz SM
    Acta Med Indones; 2015 Jan; 47(1):16-23. PubMed ID: 25948763
    [TBL] [Abstract][Full Text] [Related]  

  • 19. EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease: is universal screening appropriate?
    Byrne CD; Targher G
    Diabetologia; 2016 Jun; 59(6):1141-4. PubMed ID: 27053232
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [An interpretation of European guidelines for the diagnosis and treatment of nonalcoholic fatty liver disease].
    Xin FZ; Fan JG
    Zhonghua Gan Zang Bing Za Zhi; 2016 Jun; 24(6):403-5. PubMed ID: 27465941
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.